Imatinib interim therapy between chemotherapeutic cycles and in vivo purging prior to autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia Bone Marrow Transplantation (2005) 36, 917-918.
The Philadelphia chromosome (Ph) is the most frequent cytogenetic abnormality (20-30%) in adults with acute lymphoblastic leukemia (ALL) and has an increasing incidence with age. 1 The majority of patients with Ph þ ALL have a poor prognosis when treated with chemotherapy alone. Allogeneic stem cell transplantation (SCT) is still the only effective treatment approach to Ph þ ALL. However, 60-70% of Ph þ ALL patients are ineligible for allogeneic SCT due to their age, lack of an HLAcompatible sibling or unrelated donor, or lack of compatible cord blood. These patients can therefore be considered for autologous SCT (ASCT), although a high incidence of relapse is the main cause of treatment failure. Imatinib (Glivec, gleevec; Norvatis Pharma, Basel, Switzerland) is a potent inhibitor of the oncogenic bcr-abl tyrosine kinase. In phase I and II studies, imatinib induced overall response rates of 70-82%, including 25-55% complete remission (CR), in patients with Ph þ ALL or chronic myeloid leukemia in lymphoid blast crisis. 2 Hence, imatinib can be used for in vivo purging before ASCT, followed by maintenance therapy after transplantation.
In September 2002, a 43-year-old female experienced intermittent syncope; she was admitted to our hospital and diagnosed with Ph þ ALL in October 2002. The leukemic immunophenotype at diagnosis was CD19, CD10, CD34, CD45, TdT, MPO and HLA DR positive, and CD13, CD33, CD14, CD2 and CD5 negative. Cytogenetic analysis showed a karyotype of 46 XX, t(9;22)(q34;q11.2), and she was positive for bcr-abl minor by RT-PCR (e1a2). She was treated with two courses of HyperCVAD followed by a third cycle with high-dose cytarabine (2 g/m 2 i.v. twice daily on days 1-4) and daunorubicin (45 mg/m 2 on days 1 and 2). She achieved a complete hematologic response (CHR) after one course of HyperCVAD. She received imatinib (400 mg/day) for 4 weeks between chemotherapy cycles and for 2 weeks during a third cycle of chemotherapy for in vivo purging of leukemic blasts. She subsequently received imatinib 400 mg/day to bridge the time to ASCT.
Cytogenetic analysis showed a karyotype of 46 XX, bcr-abl fluorescence in situ hybridization (FISH) 0% and RT-PCR positive following the first and second courses of the HyperCVAD regimen, respectively, while RT-PCR showed negative conversion before the third cycle of chemotherapy. Since an HLA-matched donor could not be found, peripheral blood stem cells were collected, and FISH analysis of the stem cell preparation was BCR-ABL negative. She underwent ASCT in June 2003. Conditioning consisted of i.v. busulfan (3.2 mg/kg/day) on days À8 to À5, i.v. etoposide (30 mg/kg) once daily on day À4 and cyclophosphamide (60 mg/kg/day) on days À3 to À2. On the day of transplantation, 53.9 Â 10 6 /kg CD34 þ cells were transfused. At 21 days, FISH was 0.5% and RT-PCR negative. Beginning 42 days after transplantation, she started imatinib 400 mg/day as maintenance therapy. At 77 days after transplantation, grade 3 leukopenia (grade 2 neutropenia) and grade 2 thrombocytopenia occurred, so imatinib was withheld for 2 weeks and then reinstituted at 400 mg/day. At 279 days after transplantation, the imatinib dose was raised to 600 mg/day. However severe myelosuppression did not recur. As nonhematologic adverse events, grade 2 hepatotoxicity, vomiting, fluid retention and grade 1 nausea, and skin rash occurred. Most side effects could be managed successfully with supportive measures. At the time of writing, 2 years after transplantation, she is alive and in molecular remission (Figure 1) .
The presence of the bcr-abl translocation is the single most important adverse prognostic parameter in Ph þ ALL, with long-term survival being less than 10% with current chemotherapy regimens. 3 Although the Hyper-CVAD regimen has been found to achieve a CHR in up to 90% of newly diagnosed Ph þ ALL patients, the diseasefree survival rate is only 7%. 4 A phase 2 study of imatinib in patients with relapsed or refractory Ph þ ALL showed a CHR rate of 19%, although the response was of short duration, with a median time to disease progression of only 2.2 months. 5 This suggests that patients develop resistance to imatinib and that imatinib monotherapy is not sufficient as a first-line treatment for Ph þ ALL. Combinations of imatinib plus cytotoxic agents active against ALL, such as daunorubicin or cytarabine, have shown additive or synergistic in vitro activity, 6 supporting the therapeutic strategy used in our patient, that is, interim imatinib therapy combined with the HyperCVAD regimen and highdose cytarabine/anthracycline-based chemotherapies.
ASCT in Ph þ ALL patients has been investigated in several studies. 7 ASCT has been reported to have no advantage over conventional chemotherapy in patients with Ph þ ALL, 8 and similar results were observed in patients with a relapse rate of 70-80% postautograft. 7 High relapse rates may be due to reinfusion of leukemic cells with the graft and/ or the lack of a graft-versus-leukemia effect. In investigations of pretransplant stem cell purging prior to ASCT in Ph þ ALL, using monoclonal antibodies or cytotoxic agents, prolongation of survival could not be confirmed, and this method usually fails to achieve bcr-abl negativity. 9 Recently, it has been suggested that an effective purging strategy using imatinib may substantially enhance the treatment efficacy of ASCT in patients with chronic myeloid leukemia. 10 In addition, imatinib has been shown to have an effect on patients with relapsed or refractory Ph þ ALL. 2, 5 Hence, in imatinib-treated Ph þ ALL patients who attain molecular remission, mobilization and collection of CD34 þ cells, followed by ASCT, may represent an additional therapeutic option.
Since maintenance chemotherapy is common postremission treatment after induction chemotherapy in patients with ALL, it may also be an effective method for eradicating residual leukemic cells, thus decreasing the risk of relapse after ASCT. Thus, imatinib maintenance therapy may be a promising approach for preventing relapse after ASCT in patients with Ph þ ALL.
In summary, the results presented here suggest that imatinib combined with chemotherapy and in vivo purging of minimal residual disease before stem cell mobilization to remove Ph þ cells, followed by ASCT and imatinib maintenance therapy, appear to be an effective therapeutic strategy in patients with Ph þ ALL who do not have an HLA-matched donor. 
